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Targeted and restricted complement activation
on acrosome-reacted spermatozoa
Rebecca C. Riley-Vargas,1 Susan Lanzendorf,2 and John P. Atkinson1
1Department

of Medicine, Rheumatology Division, and 2Department of Obstetrics and Gynecology,
Washington University School of Medicine, St. Louis, Missouri, USA.

A specific hypoglycosylated isoform of the complement regulator membrane cofactor protein (MCP; CD46)
is expressed on the inner acrosomal membrane (IAM) of spermatozoa. This membrane is exposed after the
acrosome reaction, an exocytosis event that occurs upon contact with the zona pellucida. We initiated this
investigation to assess MCP’s regulatory function in situ on spermatozoa. Upon exposure of human spermatozoa to autologous serum or follicular fluid, we unexpectedly observed that acrosome-reacted spermatozoa activated the complement cascade efficiently through C3 but not beyond. Using FACS to simultaneously evaluate viability, acrosomal status, and complement deposition, we found that complement
activation was initiated by C-reactive protein (CRP) and was C1q, C2, and factor B dependent. This pattern
is consistent with engagement of the classical pathway followed by amplification through the alternative
pathway. C3b deposition was targeted to the IAM, where it was cleaved to C3bi. Factor H, and not MCP,
was the cofactor responsible for C3b cleavage. We propose that this localized deposition of complement
fragments aids in the fusion process between the spermatozoa and egg, in a role akin to that of complement
in immune adherence. In addition, we speculate that this “targeted and restricted” form of complement
activation on host cells is a common strategy to handle modified self.
Introduction
Membrane cofactor protein (MCP; CD46) is a widely expressed
complement regulator with cofactor activity for the factor I–
mediated cleavage of C3b and C4b (1–4). In addition, MCP is
a receptor for a growing list of human pathogens, including
4 viruses (5–10) and 3 bacteria (11, 12). Cross-linking MCP
produces intracellular signals in diverse cell types including
macrophages (reviewed in ref. 13), CD4+ T cells (14), and epithelial cells (reviewed in ref. 13). Recently, a deficiency of MCP has
been linked to the hemolytic uremic syndrome (15, 16).
MCP plays a role in reproduction (reviewed in ref. 13). The MCP
isoform expressed on spermatozoa is independent of the inherited
size polymorphism observed in somatic cells (17) and is hypoglycosylated secondary to trimming of the mature N-linked sugars (18).
Its binding affinity and cofactor activity for C3b and C4b, however, are comparable to those of MCP expressed by somatic cells
(2). Expression of MCP by human spermatozoa is restricted to the
inner acrosomal membrane (IAM) (19, 20), which is exposed following binding of spermatozoa to the zona pellucida (Figure 1). Variations in MCP expression on spermatozoa have been associated with
infertility (21, 22), and MCP is a target for anti-sperm Abs (23). In
mice (24), rats (25), and probably guinea pigs (26), MCP is expressed
exclusively on the IAM of spermatozoa. In these species, another
related protein, Crry, is widely expressed and performs MCP’s complement-regulatory role (27, 28). Also, Abs against MCP inhibit
binding to and penetration of zona-free hamster eggs (19, 29, 30)
Nonstandard abbreviations used: AR, acrosome-reacted; CCP1, complement control protein repeat 1; CRP, C-reactive protein; DAF, decay-accelerating factor; GVB++,
gelatin veronal buffer supplemented with Mg2+ and Ca2+; IAM, inner acrosomal
membrane; MCP, membrane cofactor protein; mHTF, modified human tubal fluid;
TRACS, targeted and restricted activation of the complement system.
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and human zona (31) by human spermatozoa. In particular, Abs
against complement control protein repeat 1 (CCP1), the aminoterminal CCP, block binding more efficiently than function-blocking Abs that bind to CCPs 3 and 4 (30). This observation led us to
evaluate MCP expression on spermatozoa of New World monkeys
(32), since they express a splice alternative of MCP lacking CCP1
on somatic cells (33). This variant may protect against infection by
measles virus, whose hemagglutinin requires CCP1 to bind MCP
(33). However, the loss of this repeat does not affect MCP’s complement-regulatory ability (33–35). Surprisingly, New World monkeys
retain expression of CCP1 on spermatozoa (32). This conservation
of structure suggests that MCP participates in fertilization, in addition to being a complement regulator.
There are several explanations for MCP’s expression on the
IAM. First, as noted, the retention of CCP1 on spermatozoa of
New World monkeys and the Ab inhibition data both suggest
that CCP1 might be playing a role in fertilization independent
of complement activation (32). Second, in 1993 Anderson et al.
described a model whereby MCP might be one half of a C3b dimer
bridge between the spermatozoa and the egg (29). The expression of complement receptors 1 and 3 on the plasma membrane
of human eggs adds support to this possibility (29). Third, the
signaling capabilities of MCP, especially the ability to induce a
calcium flux (reviewed in ref. 13), may be important on the IAM.
Fourth, MCP’s complement-regulatory activity could protect
acrosome-reacted (AR) spermatozoa during the final steps of
fertilization. Relatedly, the concentration of complement components in follicular fluid is equivalent to that in serum (36–39),
and acrosin, a protease released during the acrosome reaction, can
cleave C3 (29). However, with anti-sperm Abs and other potential
complement-activating agents in follicular fluid, it is curious that
MCP is not also expressed on the plasma membrane of spermatozoa as are 2 other complement-regulatory proteins, decay-accelerating factor (DAF) (40) and CD59 (41).
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Figure 1
Schematic representation of the acrosome reaction of human spermatozoa.
(A) The acrosome reaction of capacitated
spermatozoa occurs after binding to the
zona pellucida. (B) Upon this event, the
outer acrosomal membrane fuses with the
plasma membrane, releasing the acrosome contents. (C) MCP is expressed on
the IAM and thus is exposed following the
acrosome reaction.

To better define the role of MCP on spermatozoa, we set out to
evaluate MCP in situ as a complement regulator on spermatozoa.
Early in the course of these experiments, we recognized that AR
human spermatozoa spontaneously activate complement, and this
report represents our initial studies of this phenomenon.
Results
The IAM of spermatozoa is exposed following the acrosome reaction. Since MCP’s expression is limited to this structure, the reaction of anti-MCP specific mAb TRA-2-10 with spermatozoa provides a means to define acrosomal status (i.e., AR or nonreacted).
Spermatozoa that do not stain for MCP have an intact plasma
membrane and therefore are not AR. MCP-positive spermatozoa,
as determined by FACS, have an exposed IAM because they either
are AR or have a compromised plasma membrane. The latter possibility was assessed using membrane-impermeable dyes to mark
nonviable (i.e., membrane-compromised) spermatozoa. Consistent
with the literature, we found that approximately 25% of the spermatozoa in fresh ejaculates were in this category.
To induce the acrosome reaction, human spermatozoa were
incubated with the calcium ionophore A23187. This reagent converts between 30% and 70% of viable, nonreacted spermatozoa
to AR spermatozoa. A representative histogram of MCP expression by ionophore-treated spermatozoa is shown in Figure 2A.
Using primary labeled Abs, there is approximately a 1-log shift in
MCP expression following incubation of spermatozoa with the
ionophore. This shift represents exposure of the IAM and hence
MCP. In this sample, approximately 60% of the spermatozoa were
induced to acrosome-react. A small percentage of cells (approximately 20% for this donor) in the untreated sample were also
MCP positive. This is expected and represents the population of
spermatozoa that have spontaneously undergone the acrosome
reaction. The proportion of spontaneously AR spermatozoa varied among donors and ranged from 20% to 45% in the 4 donors
regularly used for these studies.
To examine the complement-regulatory activity of MCP on
spermatozoa in situ, experiments were designed in which spermatozoa were to be sensitized with anti-sperm Abs. As a control,
unsensitized ionophore-treated and untreated spermatozoa were
exposed to 10% autologous serum and analyzed by FACS. An
1242
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mAb against C3d was used as a marker of complement activation.
Unexpectedly, this mAb reacted with unsensitized, ionophoretreated spermatozoa. This suggests that, following the acrosome
reaction, spermatozoa activate complement (Figure 2B). To further analyze this finding, we stained for MCP and C3d on the
same population. There was a direct relationship between MCP
staining and presence of C3d antigen (Figure 3A). No staining for
C3d was observed on viable nonreacted spermatozoa (Figure 3A,
box in top left panel). This result further establishes that C3-derived
fragments deposit on AR spermatozoa. Although there was variability in the percentage of AR spermatozoa among individuals, the parallel relationship between MCP and C3d staining
was observed for each donor (Figure 3A), and the pattern was
reproducible for the same donor. The deposition on MCP-positive (AR) spermatozoa was greater (mean ± SD fluorescence for
4 donors was 313 ± 65) than on spermatozoa incubated with
heat-inactivated serum (mean ± SD fluorescence for 4 donors

Figure 2
FACS profiles of MCP and C3d on ionophore-treated spermatozoa. (A)
Calcium ionophore induces the acrosome reaction, exposing MCP to
the fluorescently labeled Ab. Approximately 20% of spermatozoa spontaneously undergo the acrosome reaction in the untreated sample. The
antibody used was Alexa Fluor 488–labeled TRA-2-10 (mAb against
MCP). (B) Spermatozoa exposed to calcium ionophore activate complement monitored by C3d deposition. The antibody used was Alexa
Fluor 647–labeled mAb against C3d. A representative experiment (out
of about 50 experiments) is shown.
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Figure 3
FACS analysis of C3d deposition on viable spermatozoa exposed to 10% autologous serum. (A) Each FACS plot represents a single donor and
is gated on viable spermatozoa. The correlation between the acrosome reaction (as measured by MCP staining) and complement deposition
(as measured by C3d staining) is observed in all 4 donors. The inset box in each FACS plot represents the MCP- and C3d-negative population.
(B) Mean C3d fluorescence of viable AR and non-AR (NAR) spermatozoa exposed to 10% normal human serum (NHS) or heat-inactivated (HI)
human serum. Mean ± SD for a minimum of 3 experiments per donor is shown.

was 34 ± 17, which is equivalent to that for the no-Ab control
samples) (Figure 3B). Complement deposition was rapid, being
maximal by 15 minutes, and there was no decrease in spermatozoa viability at 15 or 30 minutes. In addition, after 15 minutes
only approximately 1% of the viable C3-positive spermatozoa
were positive for C5b-9 neoepitope (data not shown), and there
was no decrease in spermatozoa motility. Also, we were not able
to detect C5b or C9 deposition on ionophore-treated spermatozoa by Western blot, even if the cofactor activity of MCP was
blocked with an mAb (data not shown). These data establish that
the complement deposition on AR spermatozoa is restricted to
the early complement components (through C3) and does not
decrease spermatozoa viability.
Following binding to the zona pellucida in the fallopian tubes,
which induces the acrosome reaction, the IAM of spermatozoa
is exposed to follicular fluid. We obtained neat follicular fluid
from 1 donor and follicular fluid diluted approximately 1:10
from several donors to determine whether the complement
deposition occurs in this physiologically relevant source of complement. We incubated both untreated and ionophore-treated
spermatozoa with follicular fluid and observed deposition on
AR spermatozoa (Figure 4). Results were similar whether neat
or diluted follicular fluid was used. The mean (± SD) fluores-

cence for C3d was 263 ± 19 and 219 (see legend to Figure 4) for
spermatozoa from 2 different donors incubated with follicular
fluid, compared with 387 ± 17 and 229 ± 39, respectively, for
spermatozoa incubated with 10% serum.
To evaluate the pathway responsible for complement activation, deficient, depleted, and treated human sera were used
(Table 1). Deposition of C3 fragments was prevented if the
autologous serum was heat-inactivated or treated with EDTA.
These conditions inactivate the proteases in the complement
cascade but leave C3 intact. In these conditions there was no
complement activation; this indicates that the initial activation

Figure 4
FACS analysis of viable spermatozoa exposed to follicular fluid. (A)
Each FACS plot represents a single donor and is gated on viable spermatozoa. The correlation between the acrosome reaction (as measured by MCP staining) and complement deposition (as measured by
C3d deposition) is observed for both donors. Each FACS plot is representative of 10 experiments. (B) Mean C3d fluorescence of viable spermatozoa exposed to follicular fluid (FF). Because of the limited quantity
of neat follicular fluid, only 1 experiment using donor 1 was performed.
Data for donor 3 are the mean ± SD of 3 experiments.
The Journal of Clinical Investigation
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Table 1
Complement activation by AR spermatozoa under different
serum conditions
Serum

C3d

Fluorescence (mean ± SD)

10% NHS
Heat-inactivated
EDTA
MgEGTA
C1q-depleted
C2-deficient
Factor B–depleted
C7-deficient

Yes
No
No
No
No
No
No
Yes

313 ± 65
34 ± 17
31 ± 18
32 ± 17
29 ± 14
33 ± 12
32 ± 18
289 ± 54

Calcium ionophore–treated human spermatozoa were exposed for 15
minutes to the sera noted above and then incubated with an mAb to C3d
and analyzed by FACS. Heat inactivation and EDTA treatment block all
complement activation pathways. Mg++EGTA-treated serum, C1q-depleted serum, and C2-deficient serum prevent classical-pathway activation.
Factor B–depleted serum prevents alternative-pathway activation. The
data in the first, second, and last rows represent 10 separate experiments, while the results in the other rows are from 2 experiments. NHS,
normal human serum.

of C3 is unlikely to be secondary to cleavage by an acrosomal
protease such as acrosin (29). Deposition was not observed with
C1q-depleted serum; this rules out the lectin pathway as a contributing cascade and establishes a role for the classical pathway.
This conclusion was substantiated by the finding that neither
C2-deficient sera nor Mg 2+ -EGTA–treated serum permitted
complement activation. Factor B–depleted sera also prevented
C3 fragment deposition, demonstrating a requirement for the
alternative pathway. As anticipated, a deficiency of a late complement component, in this case C7, did not affect C3 fragment
deposition. Taken together, these data support initial complement activation via the classical pathway and then amplification of the activation process through the feedback loop of the
alternative pathway.

There are several means to initiate complement activation
through C1q. First, we examined spermatozoa, following exposure to serum, for the presence of natural Ab. FACS, ELISA,
and confocal microscopy using Abs against human IgM or IgG
did not detect Ab bound to AR spermatozoa (data not shown).
Second, because C-reactive protein (CRP) initiates the classical
pathway via C1q (42) and is present in follicular fluid at levels
similar to those in serum (43, 44), we performed Western blots
and FACS analysis on ionophore-treated spermatozoa exposed
to 10% autologous serum. A CRP-specific band at 25 kDa was
observed in AR spermatozoa exposed to serum (Figure 5A). The
fainter band in the untreated sample is likely derived from spontaneously AR spermatozoa (typically 10–20% of the spermatozoa). In addition, FACS showed CRP binding to AR spermatozoa that had been exposed to 10% serum (Figure 5B). Because of
these results, CRP was absorbed from serum with beads linked
to phosphocholine. The resulting serum had a reduced ability
to activate complement on AR spermatozoa (Figure 5C). These
data demonstrate that CRP is responsible for initiating the classical complement pathway on AR spermatozoa.
Next, we used confocal microscopy to define the location of the
complement fragments. An mAb against MCP, TRA-2-10, was used
to identify the IAM (Figure 6A). After spermatozoa were exposed to
10% serum, an mAb against C3d exclusively stained the IAM (Figure 6, B and C). This demonstrates that complement activation is
restricted to the IAM and supports the FACS profile of Figure 3 in
which AR spermatozoa are shown to activate complement.
The Ab used in the FACS and confocal experiments recognizes C3d, an epitope present in all membrane-bound cleavage
fragments of C3 (Figure 7A). To determine the complement
fragments containing C3d on the IAM, we performed Western
blots with a polyclonal Ab against C3. In the lane derived from
ionophore-treated spermatozoa, the α′ chain is cleaved and α2 is
present, indicating that the C3b has been cleaved to C3bi (Figure 7B). As expected, the α1 band is barely visible, as it would
be attached via an ester linkage to proteins of varying molecular
weights expressed on the IAM. Since MCP is a cofactor for the

Figure 5
Analysis of CRP binding to AR spermatozoa. (A) Western blot of human spermatozoa. Ionophore-treated or untreated spermatozoa were exposed
to either 10% normal or EDTA-treated autologous human serum. Lysates were separated in reducing conditions by SDS-PAGE on a 10–20%
Tris-glycine gel. The primary antibody used was polyclonal goat anti–human CRP at 1:1,000 dilution. CRP is a pentamer composed of five 25-kDa
subunits. (B) FACS analysis of CRP on spermatozoa. Ionophore-treated spermatozoa were exposed to either 10% normal or heat-inactivated
autologous human serum. The primary antibody used was polyclonal goat anti–human CRP at 1:1,000 dilution. The secondary antibody used
was FITC-linked rabbit anti-goat at 1:10,000 dilution. (C) FACS analysis of spermatozoa exposed to CRP-absorbed serum. Serum was preincubated with immobilized phosphorylcholine to absorb CRP. Spermatozoa were then exposed to 10% normal serum, 10% CRP-absorbed serum,
or EDTA-treated human serum. Complement activation was measured by C3d fluorescence of viable AR spermatozoa.
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tein, because this lectin initiates the complement cascade
through C1q (42). Also, CRP concentrations in follicular
fluid are comparable to those in serum and fluctuate with
the female cycle, peaking during ovulation (43, 44). Further, since CRP activates complement on apoptotic cells
(42, 47) and nonviable spermatozoa activate complement
(48), we used 3 different nucleic dyes and examined motility to establish that viable, motile, AR spermatozoa activate
complement. CRP bound specifically to the IAM of viable,
AR spermatozoa. Consistent with its biochemical properties, heat inactivation or EDTA treatment of serum abrogated the binding of CRP to AR spermatozoa. In addition,
Figure 6
Confocal microscopy of AR spermatozoa exposed to 10% serum. Spermatozoa serum incubated with phosphocholine beads to absorb
were incubated with calcium ionophore to induce the acrosome reaction and CRP prevented C3d deposition. Taken together, these data
then exposed to 10% autologous serum. (A) The mAb TRA-2-10 labeled with indicate that CRP mediates the complement activation on
Alexa Fluor 488 recognizes MCP on the IAM. (B) An mAb to C3d labeled with the IAM of AR spermatozoa.
Alexa Fluor 647 binds to the IAM. (C) Overlay of A and B. C3d deposition is
At first glance, complement activation on viable, AR
limited to the IAM. Magnification, ×63.
spermatozoa is perplexing. If the membrane attack complex were to be formed on the IAM, there is the risk of
membrane perturbation and possibly lysis of spermacleavage of C3b to C3bi, we blocked MCP’s cofactor activity with tozoa in the final steps of fertilization. Second, spermatozoa
the mAb GB24 (45). TRA-2-10, used as a control, binds to CCP1 opsonized with C3b and C3bi are subject to immune adherence
and does not block function (45). Neither Ab inhibited the cleav- and phagocytosis. Third, the anaphylatoxins produced during
age of C3b to C3bi (Figure 7B). Factor H, a soluble complement complement activation could produce an inflammatory cell
regulator that is present in follicular fluid at levels comparable influx. Each of these points will now be addressed.
Surprisingly, complement activation on AR spermatozoa did
to those in serum (39), also cleaves C3b to C3bi. When the mAb
MH-10, which blocks the function of factor H, was used (46), the not lead to loss of motility or cell death. These data suggest
cleavage of C3b was inhibited (Figure 7B). Thus, factor H was that the complement deposition on AR spermatozoa is largely
restricted to early complement components (C1, C4, C2, and C3)
responsible for the majority of the C3b cleavage.
and does not efficiently proceed to the membrane attack comDiscussion
plex. The presence of 2 complement regulators on the IAM, MCP
The acrosome reaction is a large exocytosis event that is induced (19, 20, 49) and DAF (40), makes it difficult to envision sponin vivo when spermatozoa bind to the zona pellucida of the egg taneous complement deposition on this membrane. However,
(Figure 1). This reaction releases enzymes that degrade the protein activation by the classical pathway can overwhelm these regulamatrix of the zona and thereby allows the spermatozoa to trans- tory proteins (46). Their presence, though, is in concert with the
verse the zona and enter the perivitelline space. Our data show that hypothesis of “restricted activation” (see below) and may account
when this event occurs spontaneously or is induced in vitro, complement activation is triggered, resulting in deposition of complement fragments specifically on the IAM. Deposition was dependent on C1q, C2, and factor B, consistent with initial activation
of the classical pathway followed by engagement of the alternative
pathway amplification loop. The observation that complement
deposition on viable AR spermatozoa was C1q dependent, but
Ab independent, led us to investigate CRP as the activating proFigure 7
Western blot of C3 fragments on AR spermatozoa. (A) Diagram of C3
structure. C3 is composed of 2 chains, α and β. Upon activation, C3a
is released, leaving the truncated α′ chain of C3b. Factor I cleaves
the α′ chain in 2 locations, creating the fragments α1, α2, and C3f
(pictured in yellow). The interchain and intrachain disulfide bonds are
also shown. (B) Spermatozoa were incubated with calcium ionophore
to induce the acrosome reaction, exposed to 10% autologous human
serum, lysed, absorbed with Sepharose linked to mAb against C3d,
eluted in reducing SDS buffer, and loaded on a 10–20% gel. Lanes 1–3,
C3 standards; lane 4, AR spermatozoa incubated with 10% serum;
lane 5, spermatozoa were preincubated with the mAb TRA-2-10 and
then exposed to 10% serum; lane 6, spermatozoa were preincubated
with the mAb GB24, which blocks the complement-regulatory function
of MCP; lane 7, serum was preincubated with the mAb MH-10, which
blocks the complement-regulatory function of factor H (46).
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for why the late complement components are inefficiently deposited on viable, AR spermatozoa. These results are also consistent
with studies showing that complement activation by CRP does
not deplete the late complement components (42, 47).
Nonviable spermatozoa are known to activate the complement
cascade, producing the anaphylatoxins C3a and C5a (50, 51).
These peptides are potent chemotaxins and cellular activators
that could serve to attract neutrophils to clear the female reproductive tract of nonviable spermatozoa (50, 51). It is also likely
that these neutrophils assist in eliminating pathogens introduced
to the female genital tract. In concert with this idea, the concentration of C3 in follicular fluid increases during ovulation (52).
Under this scenario, C3b-opsonized viable spermatozoa might
be at risk for phagocytosis. However, complement activation on
AR spermatozoa occurs following binding to the zona pellucida
of the egg. There is limited, if any, opportunity for these spermatozoa to interact with a phagocyte after entering the zona pellucida. As outlined above, complement activation on nonviable
spermatozoa is likely a means of affecting their clearance. Viable
AR spermatozoa, in contrast, induce restricted targeted complement activation for a different purpose, presumably to facilitate
sperm-egg interactions.
The purpose of complement activation on AR spermatozoa
may be to coat the IAM with opsonins. Complement fragments
on spermatozoa would then facilitate egg binding, similar to
complement’s role in mediating immune adherence. Complement receptors 1 and 3 are expressed on the plasma membrane
of the egg (29). Complement is visualized as part of a highly
redundant process to facilitate sperm-egg binding. This line of
reasoning could explain why the mice deficient in C3 (53, 54), C4
(55), MCP (24), or integrins (56) are fertile. We hypothesize that
dismantling parts of the complement system in these mice eliminates a supportive pathway for fertilization but does not obliterate it. Hence, by the broad measurement of litter size, there is no
defect observed. This hypothesis provides the impetus to further
assess the sperm-egg binding in these deficient mouse strains.
The possibility of complement activation fragments interacting with complement receptors to facilitate sperm-egg binding
was first proposed in 1993 by Anderson and colleagues (29). In
that pivotal report, several mechanisms were identified whereby
spermatozoa could be coated with C3b, including alternative pathway activation, direct cleavage of C3 by the protease acrosin, and
binding of dimeric C3b to complement regulators/receptors. We
have extended and refined this study, particularly in relation to
the complement activation on AR spermatozoa. In an experimental system that quantitatively assesses viability, acrosomal status,
and complement deposition using follicular fluid, we demonstrate
that CRP binds to the IAM of viable AR spermatozoa and initiates
the classical pathway. These results are consistent with a “seeding”
of C3b by the classical pathway that in turn triggers the feedback
loop of the alternative pathway. The bound C3b is rapidly converted to C3bi by factors H and I. We therefore hypothesize that
C3bi, a ligand for integrin-related complement receptors, facilitates sperm-egg interactions.
Complement activation on viable AR spermatozoa, whether
spontaneous or induced by the calcium ionophore, has several
features that distinguish it from complement activation on foreign antigens. First, on spermatozoa, the fragment deposition
is targeted to a specific cellular location. Second, complement
activation is restricted beyond the C3 step, thereby limiting the
1246
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formation of membrane-damaging pores and release of the C5a
chemotactic factor and anaphylaxation. Third, the overall magnitude of activation up to the C3 step appears to be more tightly
controlled. It is as if this system on spermatozoa was specifically
designed to allow a measured amount of C3b to be deposited at
a specific site for a critical purpose. This concept of complement
activation on self tissue (CAST), which we propose to also call
TRACS for highly targeted and restricted activation of the complement system, is not well described as such in the literature;
however, we believe it is a common and underappreciated function of the complement system’s interaction with self tissue. In
conditions like apoptosis, ischemia/reperfusion injury, and probably other types of alterations in host cell structure, TRACS is a
preferable means to activate the complement system. In contrast
to the desirable explosion of the cascade on microbes, complement activation on an apoptotic cell is less robust, yet sufficient
to facilitate the safe and relatively noninflammatory removal of
altered self (42, 47). In the setting of ischemia/reperfusion injury, one can envision a gradient of complement activation that
correlates with the degree of cellular damage. In this example,
the goal is to rapidly and safely remove dead and dying tissue in
order to enhance wound healing and promote tissue sterility. As
previously outlined, activation on spermatozoa may represent a
situation whereby complement activation plays a role in reproduction. In these settings, regulatory proteins are present on the
cells, and it is likely the ratio of the strength and type of activation to the quantity and efficiency of the regulators that determines the outcome. Complement activation on the membrane of
Mycobacterium tuberculosis may represent an abuse of this type of
a system (57). This pathogen salvages the catalytic complement
fragment C2a of the classical pathway C3 convertase and uses it
to then deposit a limited amount of C3b on its membrane. This
deposition of C3b aids the pathogen by facilitating internalization through complement receptors.
In these experiments, one question that we set out to address
was the role of MCP on the IAM of spermatozoa. A possibility
entertained was that MCP regulated complement on the IAM.
However, blocking MCP with mAbs does not enhance or diminish C3 fragment deposition, and MCP is not responsible for the
cleavage of C3b to C3bi. MCP efficiently regulates the C5 convertase (47, 58). We therefore favor the idea that, along with DAF,
CD59, factor H, and CRP, MCP limits complement activation,
especially C5 convertase activity. However, blocking MCP function with mAb did not increase C5b-9 deposition. Activation of
complement via CRP leads to restricted C5b-9 activation (42, 47),
so MCP’s role in this situation may be redundant. A second possible role is that MCP may mediate a direct binding event between
the spermatozoa and the egg. MCP has been shown to associate
with the tetraspan CD9 on macrophages (59) and other cell types
(60). The targeted disruption of CD9 in mice results in infertility
due to the inability of spermatozoa to bind to the egg (61, 62).
Perhaps integrins associated with MCP, CD9, and tetraspans
mediate binding between the spermatozoa and the egg. Alternatively, as previously suggested, MCP may be one part of a C3b
dimer bridge with complement receptors on the egg (29), analogous to complement’s role in mediating immune adherence. A
third possibility is that complement deposition cross-links MCP
on the IAM, inducing MCP-mediated signaling events important
for fertilization (signaling through MCP is reviewed in ref. 13). A
fourth possibility is that MCP influences membrane fluidity, as
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evidenced by a role for MCP in the acceleration of the rate of the
acrosome reaction in MCP-deficient mice (24).
In summary, viable AR spermatozoa activate complement.
The complement deposition is triggered by CRP activation of
the classical pathway, followed by amplification of C3 deposition through the alternative pathway feedback loop. Complement deposition is localized to the IAM and is curtailed beyond
the C3 activation step. The purpose of this reaction remains
problematic. However, we propose that this type of targeted and
restricted complement activation is a common phenomenon on
modified self tissue.
Methods
Spermatozoa samples. Spermatozoa samples were obtained with informed
consent, and all studies were approved by the Washington University
Human Studies Committee (protocol number 94-0420). Human spermatozoa samples were repeatedly obtained from 4 healthy donors
ranging in age from 18 to 38. Fresh ejaculates were allowed to liquefy
at room temperature for 45 minutes, and then washed twice with modified human tubal fluid (mHTF) supplemented with 5% serum substitute
supplement (Irvine Scientific) and 5% HSA (100 mg/ml) (Irvine Scientific). Unless stated otherwise, centrifugation steps were performed at
200 g for 10 minutes at 4°C.
Serum preparation. Blood samples were obtained from donors that provided informed consent, and all studies were approved by the Washington University Human Studies Committee (protocol number 94-0420).
Human blood was collected in glass tubes and allowed to clot at room
temperature for 30 minutes. Samples were then centrifuged at 200 g. The
serum was placed in sterile 1.5-ml microcentrifuge tubes and maintained
at –20°C for short-term or –70°C for long-term storage.
Follicular fluid collection. Follicular fluid samples were obtained from
patients that provided informed consent, and all studies were approved
by the Washington University Human Studies Committee (protocol
number 02-1004). Follicular fluids were collected from patients undergoing in vitro fertilization. Ovarian stimulation was performed using
gonadotropins in combination with a gonadotropin-releasing hormone
(GnRH) antagonist or GnRH agonist according to established protocols. Serum estradiol was measured on cycle days 3, 5, and 7 and daily
thereafter until retrieval. Vaginal ultrasound was performed daily from
cycle day 7 onward. Human chorionic gonadotropin (5,000–10,000 IU,
Profasi; Serono Inc.) was administered intramuscularly when 3 or more
follicles were at least 16 mm in largest diameter. Transvaginal follicular
aspiration was performed 35–36 hours later. Follicles were aspirated
using a Wallace catheter (Irvine Scientific), and contents of each follicle
were collected into a 15-ml tube (Falcon 2057; Cardinal Health) containing approximately 1.0 ml of mHTF (Irvine Scientific) supplemented with
0.3 ml of sodium heparin. After the removal of oocytes, the follicular
fluids were stored at 4°C until processed. To collect pure follicular fluid,
the dominant follicle of a patient(s) was aspirated directly into a tube
that did not contain mHTF.
Acrosome reaction. The acrosome reaction was induced by incubation
of spermatozoa in supplemented mHTF media with 20 mM calcium
ionophore A23187 (Sigma-Aldrich) at 37°C for 45 minutes.
Antibodies. The mouse anti-MCP mAb TRA-2-10 was prepared at Washington University. The mouse mAb against factor H (MH-10) was donated by J. Lambris (University of Pennsylvania, Philadelphia, Pennsylvania,
USA). The mouse mAbs against human C3d and C5b-9 neoantigen were
purchased from Quidel Corp. The polyclonal goat anti–human C9 Ab
was purchased from Quidel Corp. The polyclonal goat anti–human C5
Ab was purchased from Advanced Research Technologies. Polyclonal
The Journal of Clinical Investigation

goat anti–human CRP was purchased from Affinity BioReagents. HRPconjugated rabbit anti-goat IgG (Sigma-Aldrich) was used as the secondary Ab for Western blotting. Zenon labeling kits (Invitrogen Corp.) were
used to link fluorochromes (Alexa Fluor 488 or Alexa Fluor 647) to primary Abs according to the manufacturer’s instructions (1 μg of primary
Ab was used per labeling reaction). One microgram of TRA-2-10 was
used per 1 × 106 spermatozoa, and 1 μg of either the C3d or the C5b-9
mAb was used per 2 × 106 spermatozoa for both FACS (BD Biosciences)
and confocal microscopy.
Complement deposition. AR or untreated spermatozoa were resuspended in
gelatin veronal buffer supplemented with Mg2+ and Ca2+ (GVB++) (SigmaAldrich). After incubation in 10% autologous serum or follicular fluid for
15 minutes at 37°C, the samples were washed with supplemented mHTF
media. Gelatin veronal buffer supplemented with 10 mM EDTA (SigmaAldrich) and gelatin veronal buffer supplemented with 10 mM EGTA and
7 mM magnesium chloride were also used. Sera were heat-inactivated by
30 minutes of incubation at 56°C. Sources of the C2- and C7-deficient sera
were as described in ref. 46. C1q- and factor B–depleted sera were obtained
from Advanced Research Technologies.
Viability dyes. Propidium iodide (Invitrogen Corp.), SYTOX Green
(Invitrogen Corp.), and SYBR 14 (Invitrogen Corp.) were used to assess
viability according to the manufacturer’s instructions. Results were comparable with all 3 dyes, but the different fluorescent ranges of the 3 dyes
allowed for flexibility in fluorochrome usage.
FACS analysis. Spermatozoa, after exposure to a complement source,
were incubated with Zenon-labeled primary Abs (described above) for
30 minutes at 37°C in supplemented mHTF and then washed twice.
Flow cytometry was performed with a FACSCalibur (BD Biosciences)
using forward and side scatter thresholds optimized for spermatozoa.
A minimum of 10,000 events were collected per sample. Samples were
gated on viable spermatozoa.
Lysates. Spermatozoa were resuspended in lysis buffer (PBS containing
1% NP-40, 0.05% SDS, and Complete protease inhibitor cocktail tablets
[Roche Diagnostics Corp.]) and incubated for 30 minutes at 4°C. Samples
were centrifuged at 13,500 g for 15 minutes at 4°C. Supernatants were
transferred to 1.5-ml microcentrifuge tubes and stored at –20°C.
Immunoabsorption. Polyclonal goat anti–human C3 was coupled to CNBractivated Sepharose (Amersham Biosciences) according to the manufacturer’s suggestion. Spermatozoa lysate (50 μl), coupled Sepharose (50 μl),
protease inhibitor tablets (Roche Diagnostics Corp.), and cell lysis buffer
were combined and incubated at 4°C overnight with “end over end” mixing.
The Sepharose beads were next washed 3 times with 0.3% NP-40. Eluates,
obtained by boiling of the Sepharose beads in SDS loading buffer, were
used for Western blotting as described below.
Western blotting. Cell lysates were separated in a 10–20% SDS-polyacrylamide
gel under reducing conditions and then transferred onto nitrocellulose membranes using the NOVEX MiniCell II wet blotting system (Invitrogen Corp.).
The membranes were blocked with 5% nonfat dry milk powder in 1× Tris-buffered saline (TBS) and 0.05% Tween-20 (TBS-T) (Sigma-Aldrich) overnight at
4°C. After 3 washes in TBS-T, the membranes were incubated in blocking buffer for 1 hour at 37°C with either purified polyclonal goat anti-CRP (1:1,000)
or polyclonal goat anti-C3 Ab (1:7,500). Blots were washed 3 times and then
incubated in blocking buffer for 1 hour at room temperature with HRP-conjugated rabbit anti-goat IgG secondary Ab (Sigma-Aldrich) (1:10,000). After
washing, the signals were developed using the enhanced chemiluminescence
kit from Pierce Biotechnology Inc. The bands were visualized by exposure of
the membranes to BioMax MR film (Eastman Kodak Co.).
ELISA for human IgM. The Microwell ELISA (Diagnostic Automation Inc.)
was used to assess total human IgM in spermatozoa lysates according to
the manufacturer’s instructions.
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Confocal microscopy. Spermatozoa were incubated in the fluid phase with
Zenon-labeled primary Abs (described above) for 30 minutes at 37°C in
supplemented mHTF. After the samples were washed twice with supplemented mHTF media, a 1:1 dilution of sample and ProLong Antifade
Reagent (Invitrogen Corp.) was placed on a slide and analyzed with an LSM
510 META confocal microscope (Carl Zeiss Inc.).
CRP absorption. Immobilized p-aminophenyl phosphorylcholine beads
(150 μl; Pierce Biotechnology Inc.) were added to human serum diluted
1:10 with GVB++ buffer. The samples were incubated at room temperature
for 30 minutes with gentle mixing. After centrifugation at 200 g for 5
minutes, the supernatant was removed and used as a complement source
for FACS experiments.
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